Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.

Trial Profile

A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms SUNRISE
  • Most Recent Events

    • 26 Dec 2018 Status changed from recruiting to completed, as reported in an article published in the Journal of Clinical Oncology.
    • 26 Dec 2018 Results published in the Journal of Clinical Oncology
    • 06 Jun 2017 Results assessing the feasibility and tolerability of high dose, once weekly (1w) or once every two weeks (2w) sunitinib in patients with advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top